Genentech was founded in 1976. Since its founding in 1976, Genentech has made its headquarters in South San Francisco, California. Starting with one rented building and two staff members, the company's South San Francisco site has grown to 48 buildings and approximately 5,700 employees. Today, the South San Francisco site is home to a research center, manufacturing operations and various business functions. Genentech's Vacaville, California site is located on 100 acres in Solano County, approximately 50 miles northeast of San Francisco. Acquired in 1994, it was first licensed to produce a biologic in 2000. Genentech's Oceanside Product Operations was purchased in June 2005. It is a state-of-the-art biologics manufacturing facility with approximately 330 employees. Genentech currently intends to hire approximately 200 additional employees at the facility by the end of 2006. Upon U.S. Food and Drug Administration (FDA) licensure expected in the first half of 2007, the Oceanside facility will add 90,000 liters of capacity that will be initially dedicated to producing Avastin bulk drug substance. The facility is located on 60 acres in Oceanside, California, about 35 miles north of San Diego. Located in the Pontevedra province of Galicia, in Spain's northwest corner, Genentech's Porriño facility was acquired in 2000. It is the first Genentech site outside the United States and the headquarters of Genentech España, Genentech's wholly-owned subsidiary company. Genentech's mission is to be the leading biotechnology company, using human genetic information to discover, develop, manufacture and commercialize biotherapeutics that address significant unmet medical needs. Genentech commits itself to high standards of integrity in contributing to the best interests of patients, the medical profession, its employees and its communities, and to seeking significant returns to its stockholders, based on the continual pursuit of scientific and operational excellence.